Is Cosmo N.V. (0RGI.L) a Buy, Sell, or Hold?
LSE : 0RGI.L
Cosmo N.V.
$64.7 CHF
$1.2 (1.89%)
- Volume
- 1K
- Average Volume
- 1.44K
- Market Capitalization
- $1.05B
- P/E Ratio
- -302.17
- Dividend Yield
- 3.02%
- Price Target
- Year High
- $68.60
- Year Low
- $33.75
- Day High
- —
- Day Low
- —
- Payout Ratio
- -$8.99
- Current Ratio
- $7.18
Company Overview
LSE
Giovanni di Napoli
Medical - Pharmaceuticals
Healthcare
0RGI.L
324
IE
CHF
Liquidity Metrics
0.01
7.18
6.77
2.19
-8.99
Sales & Valuation
$104.85M
11.42
2.30
-74.48
-1.00
Profitability
-$0.23
-$3.63M
-3.46%
-0.88%
-0.77%
-0.59%
P/E Metrics
-302.17
2.94
2.94
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
7.76
8/9
$157.63M
$612.16M
$123.36M
$143.16M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Federico Sommariva | Chief Legal Counsel |
| Mauro Severino Ajani | Founder & Non-Executive Director |
| Niall Donnelly | Executive Vice President of Corporate Governance, Chief Sustainability Officer & Executive Director |
| Silvia Miliani | Chief HR Officer |
| Svetlana Sigalova | Chief Financial Officer |
| Giovanni Di Napoli | Chief Executive Officer & Director |
| Luigi Longo | Chief Scientific Officer |
| Ngo Dinh Nhan | President of Cosmo Intelligent Medical Devices |
| Davide Malavasi | Qualified Person & Technical Director |
| Alessandro E. Della Cha | Non Executive Chairman |
Poll Results
No votes yet today — be the first to share your view!
About Cosmo N.V. (LSE:0RGI.L) Stock
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesion ... s during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. The company was founded in 1997 and is headquartered in Dublin, Ireland.
Frequently Asked Questions
-
What is the current Cosmo N.V. (0RGI.L) stock price?
-
Cosmo N.V.(LSE:0RGI.L) stock price is $64.7 in the last trading session. During the trading session, 0RGI.L stock reached the peak price of $68.6 while $33.7496 was the lowest point it dropped to. The percentage change in 0RGI.L stock occurred in the recent session was 1.89% while the dollar amount for the price change in 0RGI.L stock was $1.2.
-
0RGI.L's industry and sector of operation?
-
The LSE listed 0RGI.L is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
-
Who are the executives of 0RGI.L?
-
Federico Sommariva | Chief Legal Counsel
Mauro Severino Ajani | Founder & Non-Executive Director
Niall Donnelly | Executive Vice President of Corporate Governance, Chief Sustainability Officer & Executive Director
Silvia Miliani | Chief HR Officer
Svetlana Sigalova | Chief Financial Officer -
How many employees does 0RGI.L have?
-
Number of 0RGI.L employees currently stands at 324. 0RGI.L operates from Riverside 2, Dublin, DU D02 KV60, IE.
-
Link for 0RGI.L official website?
-
Official Website of 0RGI.L is: https://www.corero.com
-
How do I contact 0RGI.L?
-
0RGI.L could be contacted at phone #353 1 817 0370 and can also be accessed through its website. 0RGI.L operates from Riverside 2, Dublin, DU D02 KV60, IE.
-
How many shares of 0RGI.L are traded daily?
-
The average number of 0RGI.L shares traded daily for last 3 months was 1.44K.
-
What is the market cap of 0RGI.L currently?
-
The market value of 0RGI.L currently stands at $1.05B with its latest stock price at $64.7